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Quinolone derivative, particularly fluoroquinolones are important synthetic antimicrobial 
agents. Currently some quinolone derivatives are under investigation for the treatment of 
multidrug-resistant tuberculosis (MDR-TB) and extensive drug resistance tuberculosis 
(XDR-TB), and are under investigation as first-line anti-TB drugs. The main biological 
objective in Mycobacterium tuberculosis is the DNA gyrase, a topoisomerase II encoded 
by gyrA and gyrB that is necessary to retain the DNA supercoil. Mutations in short 
regions of DNA gyrase are associated with quinolone resistance and take place in several 
MDR clinical isolates of M. tuberculosis. The new quinolone derivatives, isoniazid-
fluoroquinolones and triazoloquinolone derivatives are representatives of a new class of 
potent and selective anti-TB agents. The esters of triazoloquinolone derivatives are with 
absence of cytotoxicity. Furthermore, they are particularly interesting is their activity 
against MDR-TB and XDR-TB. 
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1. INTRODUCTION_________________________________________ 
Tuberculosis (TB) is one of the most widespread infectious diseases, concerning one-third of world's 
population (about 2 billion people) infected with Mycobacterium species, mainly M. tuberculosis. 
Every year, approximately 8 million of the TB infected people develop active TB, and almost 2 
million die of the disease and approximately one life is lost due to TB every 15 seconds. According 
to the 2011 Global TB Control Report of the World Health Organization (WHO), in 2010 650,000 
cases of MDR-TB emerged among the world’s 12 million prevalent cases of TB [1,2]. Even more 
terrifying is the appearance of multi drug resistant tuberculosis (MDR-TB) and extensively drug 
resistant tuberculosis (XDR-TB) reported in all around the world. The increased number of MDR 
strains, is closely associated to the growing global HIV/AIDS pandemic [3]. The connection of TB 
and HIV infections is so dramatic that, in some cases, almost two-thirds of the patients diagnosed 
with TB are also HIV-1 positive [4], and the risk of developing TB is between 20 and 37 times 
greater in people living with HIV than among those who do not have HIV infection [5]. TB is the 
leading cause of death among HIV infected people. TB accounts for more than a quarter of deaths 
among people living with HIV worldwide [6,7]. Since HIV infection is a major risk factor for the 
development of active TB which, in turn it is a cofactor in the expansion of HIV infection [8]. The 
immune suppression linked to HIV infection has also caused the emergence of many infections, like 
M. avium complex (MAC) infections [9-11]. M. avium complex (MAC) infections can cause severe 
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illness in people with advanced AIDS but rarely affects others [12-14]. Since the introduction of 
highly active antiretroviral therapy (HAART), the rate of MAC infection has substantially declined. 
Current treatment of disseminated MAC infection includes the use of macrolides (clarithromycin or 
azithromycin) in combination with ethambutol, or rifabutin. These drugs increase overall the patients 
survival time , however treatment must be continued indefinitely in patients with advanced AIDS or 
discontinued after at least 12 months in those who are also treated with HAART and experience 
immune reconstitution [15].  Although the introduction of HAART has significantly contributed to 
reduce the frequency and improve the outcome of MAC infection, this remains an important 
complication of AIDS for which new therapeutic approaches are needed. One of the main problems 
faced is that the in vitro susceptibility  testing results of non-tuberculous mycobacteria do not 
correspond with how these bacteria respond to treatment in patients [16]. In M. tuberculosis the 
existence of hetero-resistance has also been shown when the presence of mutations associated with 
resistance to certain drugs is genetically studied [17]. In order to improve these problems, a 
significant effort is being made to standardize methods of studying the susceptibility of these 
microorganisms in vitro. In the latter editions of the National Committee for Clinical Laboratory 
Standards (NCCLS), there are also included recommendations to evaluate the in vitro activity of M. 
chelonae, M. abscessus, M. fortuitum, M. avium complex (MAC), M. marinum and M. kansasii 
[18,19], these systems being already proved to provide acceptable results for of the study of M. 
tuberculosis susceptibility to isoniazid and rifampicin only [20]. In the recent years efforts have been 
made to standardize the in vitro susceptibility tests, especially of M. tuberculosis to fluoroquinolones 
[21]. With regard to non-tuberculous mycobacteria, susceptibility testing for baseline MAC isolates 
from AIDS patients not previously treated with clarithromycin or azithromycin does not appear to be 
useful in guiding therapy [22]. Furthermore, the treatments currently used for TB are prolonged and 
may produce important side effects, especially when the strain is resistant to isoniazid and 
rifampicin. Therefore, the Global Alliance for Tuberculosis Drug Development recommends that in 
order to stop the spread of TB it is necessary to develop new fast acting drugs [23]. Moreover, it is 
very important to try to prevent primary resistance emerging and limit the spread of resistant strains 
[24], since recently there has been great concern about the increasing spread of MDR strains [25,26]. 
2. THE MOST PROMISING DRUGS__________________________ 
In order to alleviate this problem, many experimental studies have been done and the new 
fluoroquinolones (moxifloxacin and gatifloxacin) and linezolid have been shown to exhibit good in 
vitro activity against M. tuberculosis and against other mycobacteria [27]. The good activity of these 
compounds has been verified in animal models, and moxifloxacin is known to have potent activity 
against both actively multiplying and non-actively multiplying tubercle bacilli. Using a murine 
model, the combination of moxifloxacin, rifampin and pyrazinamide has been seen to reduce the 
time needed to eradicate M. tuberculosis from the lungs of infected mice by up to 2 months when 
compared to the standard regimen of isoniazid, rifampin and pyrazinamide [27], although this has 
not been demonstrated in humans [28]. The rapid development of fluoroquinolone resistance in M. 
tuberculosis has also been reported [29]. Linezolid has proved to be useful in the treatment of some 
cases of MDR-TB, but its prolonged use is frequently associated with toxicity, mainly anaemia and 
peripheral neuropathy [30]. Some drugs of  rifampicin family, such as rifalazil, rifapentin, and 
rifabutin, have also been proved to be useful. For example, in mouse, rifalazil in combination with 
isoniazid have been found to be more active than rifampin/ isoniazid [31]. As far as treatment of 
non-tuberculous mycobacteria is concerned, the new fluoroquinolones exhibit good activity against 
M. kansasii and M. fortuitum, and linezolid is active against M. kansasii [32]. Latent TB infects one-Chhavi Asthana, Mohammad Asif 
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third of the world and its treatment may be the basis for controlling this disease in the future, 
provided that the right drugs are found. With this end in mind, models that attempt to mimic the 
latent state are being developed [33]. The combination of rifapentine and isoniazid was better 
tolerated than the combination of rifampin and pyrazinamide and was associated with good 
protection [34]. In the case of MAC, the efficacy of treatment with azithromycin and thiacetazone is 
being evaluated, as well as the efficacy of clarithromycin compared with that of azithromycin, and 
that of the clarithromycin/etambutol combination compared with rifabutin or clofazimine [35,36].  
3. CHEMOTHERAPY OF TUBERCULOSIS____________________ 
Earlier to the beginning of effective chemotherapy of TB, 50% of patients with active pulmonary TB 
died within 2 years. Since 1940s the introduction of the combination of streptomycin and para-
aminosalicylic acid in therapy and successively, the addition of isoniazid, ethambutol, rifampin and 
pyrazinamide, used in various combinations, resulted in a significant decrease in the mortality. These 
drugs are recommended as first-line therapy [37]. However, quinolines are classified as second-line 
drugs, since their use in TB treatment still remains controversial [38]. They are recommended and 
suggested in managing MDR-TB and XDR-TB, due to the fact that they have a broad and potent 
spectrum of antimicrobial activity and can also be administered orally, giving a better chance of cure 
and preventing the development and spread of further resistance [39].  
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Figure 4: Fourth generation quinolone compounds 
The 4-quinolones-3-carboxylic acid, typical of quinolones, have been reported to display “non-
classical” biological activities, such as antitumor, anxiolitic, anti-ischemic, anti-HCV-NS3 helicase 
and NS5B  polymerase activities, anti-HSV-1, anti-HIV-1 integrase and CB-2 agonists [40,41]. 
However, quinolones remain one of the most widely prescribed antibiotics. Generally quinolones are 
classified in four generations. The first generation is represented by quinolones without fluorine as 
nalidixic acid, cinoxacin and oxolinic acid (Figure 1); the second one by norfloxacin, ciprofloxacin, 
ofloxacin, enoxacin and lomefloxacin (Figure 2); the third one by levofloxacin, sparfloxacin and 
gatifloxacin (Figure 3) and the fourth generation is represented by moxifloxacin and trovafloxacin 
(Figure 4) [42]. The most recent fluoroquinolones (FQs) are being evaluated as potential anti-TB 
drugs, also for their potential to shorten TB treatment duration, one of the major strategies for TB 
control [43,44].  The use of levofloxacin or moxifloxacin for the treatment of XDR-TB, defined as 
resistance to isoniazid, rifampicin, a FQ and a second-line injectable drug, even when ofloxacin 
resistance is present [45,46]. 
4.  FLUOROQUINOLONE DERIVATIVES-MODIFICATIONS, 
RESEARCH TRENDS________________________________________ 
A great amount of work has been done in order to acquire useful knowledge about mechanism of 
action and resistance to available anti-TB agents. Fluoroquinolones has been one of the most 
effective anti-TB drugs used in clinical practice. The antimycobacterial pharmacophore moiety of 
fluoroquinolones have been introduced in a number of various types of molecules to prepare simple 
or more complicated compounds to improve their activity against Mycobacteria sp., and their MDR 
strains. All these fluoroquinolone molecule modifications are possessing at least medium anti-TB 
activity. The reported fluoroquinolones derivatives are classified according to their structure. Chhavi Asthana, Mohammad Asif 
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Table 1: Quinolones that inhibit M. tuberculosis DNA gyrase activity and growth (Concentration in µg/mL). 
Quinolones  IC50  CC50  MIC  Quinolones  IC50  CC50  MIC 
Sparfloxacin  2  5  0.25  Trovafloxacin  15  25  16 
Sitafloxacin  2.5  2  0.25  Grepafloxacin  16  15  1 
Clinafloxacin  2.5  5  0.5  Peflofloxacin  37  40  8 
Gatifloxacin  3  4  0.12  Tosufloxacin  37  25  16 
Ciprofloxacin  3.5  6  0.5  Temafloxacin  40  35  4 
Floxifloxacin  4.5  4  0.5  Flerofloxacin  45  50  6.25 
Levofloxacin  5  12  0.5  Enofloxacin  50  25  8 
Oflofloxacin  10  20  1  Oxolinic acid  300  -  32 
Gemifloxacin  11  6  4  Flumequin  500  -  64 
Garefloxacin  13  15  2  Pipemidic acid  1000  -  128 
Norfloxacin  14  40  4  Nalidixic acid  1100  -  128 
 
5. NEW CLASS OF QUINOLONE DERIVATIVES 
TRIAZOLOQUINOLONES___________________________________ 
Triazolo[4,5-f]quinoline-8-carboxylic acids exhibited in  vitro  antibacterial activity against both 
gram-positive and gram-negative bacteria. As for the C-5 substituents, a fluorine atom was the most 
favorable of the three groups, H, F, and Cl [47]. In the last decade, various quinolone compounds 
have been reported to have antitubercular activity. M. tuberculosis isolates expressing resistance to 
both isoniazid and rifampin are susceptible to fluoroquinolones. The activity of triazolo[4,5-
h]quinolone-carboxylic acids, a new class of compounds active against MDR-TB. This novel class 
of quinolones is endowed with a selective anti-TB activity, coupled with absence of cytotoxicity. 
The new derivatives showed that the methyl group is the most effective substituent in both N-3 and 
N-9 positions of the ring system [48]. Quinolone derivatives, 3-methyl-9-substituted-6-oxo-6,9-
dihydro-3H-[1,2,3]-triazolo [4,5-h]quinolone-7-carboxylic acids and their ethyl esters parents 
(Figure 5; compounds 1-34)  have anti-TB activity [49-52]. 
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13  CH3  CH2-cyclobutyl  30  CH3  CH2-cyclobutyl 
14  CH2Ph  CH3  31  CH2Ph  CH3 
15  CH2Ph  CH2CH3  32  CH2Ph  CH2CH3 
16  CH2Ph  CH2CH=CH2  33  CH2Ph  CH2CH=CH2 
17  CH2Ph  CH2CH2CH2CH3  34  CH2Ph  CH2CH2CH2CH3 
Figure 5: Chemical structure of [1,2,3]triazolo[4,5-h]quinolone compounds 1-34 
All compounds anti-TB in vitro activity have been evaluated in comparison with standard anti-TB 
drugs. The results showed that [1,2,3] triazolo[4,5- h]quinolones exhibited a good anti-TB activity, 
without cytotoxicity [48]. Compounds 10, 27 and 31 showed the best activity against mycobacteria. 
Among them, compound 10 was the most potent against H37Rv and H37Ra (MIC90 = 0.5μg/mL), 
and 11 clinical isolates of MDR-TB (Table 2) [50]. The small, electron donor methyl group in 
position N3 gave the best results, since the introduction of an increasing steric effect substituent (as 
the benzyl group) led to a loss of the biological effect, like as more lipophilic and bulking 
substituents at the N9 position. Lastly, when MICs were determined against gram-positive and gram-
negative bacteria and against Candida sp. all compounds were inactive (MIC > 64-100μg/mL) [53].  
Table 2: In-vitro evaluation of triazoloquinolone compounds 10, 27, 31 against Mycobacterium (MIC:µg/mL) 
 Compound  M. tuberculosis 
H37Rv 
M. tuberculosis 
H37Ra 
M. smegmatis mc
2 
155 
M. bovis 
10  0.5  0.5  5  4 
27  16  8  32  16 
31  8  4  32  4 
Ethambutol  5  4  0.5  2 
Rifampin  <0.5  <0.06  8  - 
Streptomycin  1  1  -  - 
Ciprofloxacin  0.5  0.5  0.125  0.25 
 
6. ISONIAZID-FLUOROQUINOLONES_______________________ 
The adducts of isoniazid with antibacterial fluoroquinolones 35 and 36 exhibited the MIC value 
[μmol]  of  1.30 and 1.26 respectively. The fluoroquinolone-isoniazid derivatives showed higher 
activity than the above discussed quinolone-isoniazid derivatives 35 and 36 (fig 5) [54]. Further 
indolyl-isoniazid-flouroquinolone derivatives 37-40  were prepared [55]. All compounds are 
substituted by anti-TB active gatifloxacin at the same time. All compounds 37-40 are more lipophilic 
than gatifloxacin, which is important for penetration of these com-pounds through 
bacterial/mycobacterial cell. Assuming the issue of penetration is even more crucial for quinolone 
activity against Mycobacteria sp. All compounds were tested against M. tuberculosis, and against 
MDR-TB and they showed similar activity. According to the results, it can be assumed, that 
unsubstituted gatifloxacin exhibited higher activity against M. tuberculosis, whereas prepared 
analogues 37-40 (fig 6) showed good efficacy against MDR-TB strains. All the compounds were 
also evaluated for their cytotoxicity and all the discussed derivatives were found to be non-toxic until 
62.5µg/ml. Combination of isoniazid with other appropriate antibacterial component leads to the 
prodrugs with prolonged release and possible synergism as compound 41. Their activities are 
comparable with fluoroquinolone not only against M. tuberculosis H37Rv, but they exhibited 
activity also against some clinical isolated atypical strains.  MIC value of compound 41  (fig  7) 
against various mycobacterium were M. tuberculosis H37Rv (-μmol/l) M. tuberculosis 331/88 (2.0 Chhavi Asthana, Mohammad Asif 
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μmol/l) M. avium 330/88 (125 μmol/l) M. kansasii 235/80 (2.0 μmol/l) and M. kansasii 6509/96 (2.0 
μmol/l) [56,57]. 
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Figure 6: Fluoroquinolone-isoniazide derivatives 35 and 36 
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Figure 7: Indolyl-gatifloxacin-isoniazid derivatives 37-40, their MIC value against M. tuberculosis, and 
against MDR-TB strains. The MIC value of gatifloxacin was 0.20 μg/ml, or 3.12 μg/ml 
N
O
OH
O
N
N N
H
N
O
N
F
 
41 
Figure 8: The antitubercular effect of fluoroquinolone-isoniazid derivatives 
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7. DISSCUSSION____________________________________________ 
In view of the persistent drug-resistant (MDR-TB/XDR-TB) problems to currently used anti-TB 
agents, it is important that new anti-TB agents should address different targets, as those of currently 
used drugs including the shortening of TB therapy. The unique structure of the mycobacterial cell 
wall makes it a useful target for drug development and studies can be directed to specific sites. 
Although one possible long term solution to the problem is a better vaccine, in the short term, the 
major reliance will be on chemotherapy
 requiring the development of novel, effective and non-toxic 
anti-TB agents to control TB. However, in recent years, there is an enhanced activity in the research 
and development of new drugs for TB. Some compounds are presently in clinical development, 
while others are being investigated pre-clinically in an attempt to explore new molecules for the 
target based treatment of TB [1,42,]. Simultaneously, some new targets are being identified and 
validated for their practical usefulness. The specific goal would be to bring new, affordable TB 
agents that would reduce duration of treatment, effective against latent infections andagainst MDR-
TB/XDR-TB, cheap and easily available [32,58].  Thetriazolo[4,5-h]quinolone-carboxylic acid 
derivatives have specific anti-TB potential. This characteristic is quite relevant in the context of a new 
anti-TB drug for two main reasons. First, the limited spectrum should not disturb the existing normal 
flora and, therefore, should likely be better tolerated as compared with wide spectrum existing 
treatments. Second, the selectivity of the antimicrobial activity should limit the selection of resistant 
mutants among species that are not specifically targeted by the treatment, therefore reducing the risk 
of vertical transmission of resistance across species. 
8. Conclusions___________________________________________ 
The triazolo[4,5-h]quinolone-carboxylic acid derivatives belong to a novel class of quinolones 
endowed with a selective anti-TB activity. The comparison of the new derivatives with the previous 
series shows that the methyl group is the most effective substituent in both N-3 and N-9 positions of 
the ring system. In conclusion, these new quinolones are particularly adapted to be used as anti-TB 
agents. Finally, the selectivity and the consistent ability to reduce the onset of cross resistance of 
triazoloquinoles, probably due to their different mechanism of action, lead them to be good 
candidates for further development of new anti-TB drugs. 
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